Company: HURA
Filing Date: 2025-09-18
Form Type: S-1/A
Source: 0001193125-25-207395
Chunk: 335

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-09-18
Form: S-1/A
Chunk 335
---
:-------------------------------------------------------|:----|:------------|-----------:|:----|:------------------------------|---------:|:----|:-----------------|
| Historical TuHURA common stock warrants                |     |             | 10,592,387 |     | $                             |     4.16 |     | February 2025    
 August 2029      |
| Historical Kintara common stock warrants               |     |             |     17,468 |     | $                             | 1,362.41 |     | March 2025       
 April 2027       |
| 2024 common stock warrants issued to financial advisor |     |             |    297,029 |     | $                             |     0.01 |     | April 2027       |

Warrant modification

In August 2024, the Company extended the exercise period of its common stock purchase warrants issued in connection with Legacy TuHURA Series A Preferred Stock (the “Series A Warrants”) for an additional six months, with a new expiry date of February 12, 2025. There were no other changes in the terms of the Series A Warrants. As a result, a deemed dividend to the holders of the Series A Warrants in the amount of $ 965,177 was recorded as an increase in the net loss attributable to the common stockholders for the year ended December 31, 2024. The incremental value associated with the warrant modification was determined using a Black-Sholes pricing model using the original terms of the warrants and the modified terms of the warrants and the following assumptions: expected term of approximately 0.1 - 0.6 years, dividend yield of 0.0 %, volatility of 75 % - 112%, and a risk free rate of 5.4 % to 5.5 %.

Financial advisor warrants

There were 297,029 warrants issued to our financial advisor, H.C. Wainwright & Co., LLC., related to merger transaction costs in connection with the reverse merger with Kintara. The warrants are considered “penny” warrants and are considered common stock outstanding as of December 31, 2024 (see note 4). The accounting for the warrants is determined to have zero net effect on total equity as of December 31, 2024. The fair value associated with the warrants was determined using Black-Sholes pricing model using the terms of the agreement and the following assumptions expected term of approximately 2.4 years, dividend yield